Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

NCT06546423 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Human Metapneumovirus
Human Parainfluenza Virus Type 3

Interventions

BIOLOGICAL: B/HPIV3/HMPV-PreF-A vaccine
BIOLOGICAL: B/HPIV3/HMPV-F-B365 vaccine
DRUG: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]